COVID-19; prescriptions for hydroxychloroquine and ivermectin for treatment.
Impact
If enacted, SB793 will officially recognize and permit the use of hydroxychloroquine and ivermectin as treatment options for COVID-19 within the state. This legislation could have significant implications for the medical community, as it would not only protect prescribers from liability associated with prescribing these medications but also potentially increase their availability to patients. This move may reflect a growing trend among certain health care professionals to explore various treatment options for COVID-19, potentially leading to broader discussions around the efficacy and safety of such treatments.
Summary
SB793 seeks to amend the Code of Virginia to allow licensed health care providers to prescribe, administer, or dispense hydroxychloroquine and ivermectin for patients diagnosed with COVID-19. The bill specifically states that medical professionals will not face disciplinary action from the Board of Medicine for prescribing these medications, provided that such actions are documented in the patient's medical record. By introducing this provision, the bill aims to remove barriers for providers who choose to utilize these treatments based on their clinical judgment regarding COVID-19 patients.
Contention
The discussion surrounding SB793 has potential for notable contention, particularly regarding the medical community's divided opinions on the effectiveness of hydroxychloroquine and ivermectin in treating COVID-19. Critics may argue that endorsing these medications without sufficient evidence could lead to misuse or detract from more proven therapeutic strategies. Additionally, there may be concerns regarding the implications of providing immunity to prescribers, which some may view as a loophole that could allow for questionable medical practices. Thus, the bill's passage could spark debate over the balance between encouraging innovative treatments and ensuring patient safety.
Authorize the dispensing of ivermectin and hydroxychloroquine under a written protocol developed by a health care provider, and to provide liability protection therefor.
Pharmaceuticals; prohibiting the Board of Pharmacy from disciplining pharmacists who recommend off-label use of a drug; allowing over-the-counter sale of Ivermectin and Hydroxychloroquine.